The thing is there has been a material change in ecq valuation from the acquisition of cynata. Details are light on, but management have been bolstered to get this one up and about.
Top 20 hold 65% + I believe so there are not that many shares out there. Stem cell companies are also getting more favourably looked at as the bio space continues to grow.
Cynata has patent protection until 2028. They have gained 1 key patent and are filing another - due shortly.
I'm holding tight to 10+ as this looks a great opportunity here.
ECQ Price at posting:
2.9¢ Sentiment: Buy Disclosure: Held
